Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 19, 2021

Primary Completion Date

September 7, 2022

Study Completion Date

November 30, 2022

Conditions

Dermatitis Atopic

Interventions

DRUG

Dupilumab SAR231893

Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)

Trial Locations (3)

Investigational Site Number :8400001, Denver

Investigational Site Number :8400002, Los Angeles

Investigational Site Number :8260001, Sheffield